Evidence map›Paper›PMID 29151525›Full record

ArticleInternal medicine (Tokyo, Japan)2018

Achromobacter Infection Is Rare in Japanese Patients with Pulmonary B-cell Lymphoma.

Satsuki Aoyama, Ayako Masaki, Yuma Sakamoto, Hisashi Takino, Takayuki Murase, Koichi Ohshima, Tadashi Yoshino, Seiichi Kato, Hiroshi Inagaki

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. [Research Progress of Pulmonary Extranodal Marginal Zone Lymphoma].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024
    Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Satsuki AoyamaDepartment of Pathology and Molecular Diagnostics, Nagoya City University Graduate School of Medical Sciences, Japan.
Ayako MasakiDepartment of Pathology and Molecular Diagnostics, Nagoya City University Graduate School of Medical Sciences, Japan.
Yuma SakamotoDepartment of Pathology and Molecular Diagnostics, Nagoya City University Graduate School of Medical Sciences, Japan.
Hisashi TakinoDepartment of Pathology and Molecular Diagnostics, Nagoya City University Graduate School of Medical Sciences, Japan.
Takayuki MuraseDepartment of Pathology and Molecular Diagnostics, Nagoya City University Graduate School of Medical Sciences, Japan.
Koichi OhshimaDepartment of Pathology, Kurume University School of Medicine, Japan.
Tadashi YoshinoDepartment of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan.
Seiichi KatoDepartment of Pathology and Laboratory Medicine, Nagoya University Hospital, Japan.
Hiroshi InagakiDepartment of Pathology and Molecular Diagnostics, Nagoya City University Graduate School of Medical Sciences, Japan.
Nagoya City University · JPKurume University · JPNagoya University Hospital · JPOkayama University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective Achromobacter xylosoxidans (A. xylosoxidans) has been recently reported to have an association with the development of pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma in patients from European countries. However, the prevalence rates for A. xylosoxidans may vary significantly from country to country. To assess this association, the prevalence of A. xylosoxidans was analyzed in Japanese patients with pulmonary B-cell lymphoma. Methods DNA samples were obtained from formalin-fixed, paraffin-embedded sections of pulmonary MALT lymphomas (n=52), diffuse large B-cell lymphomas (DLBCLs, n=18), and benign pulmonary lesions (n=19). All samples were histopathologically reviewed by experienced hematopathologists, and the clonality of all MALT lymphoma cases was confirmed by a polymerase chain reaction (PCR)-based IGH rearrangement clonality assay. They were also tested for the API2-MALT1 fusion transcript. The presence of bacterial DNA was assessed with a nested PCR, and DNA sequencing was performed to confirm the PCR specificity. Results A. xylosoxidans DNA was detected in 1/52 cases of pulmonary MALT lymphoma, 2/18 cases of DLBCL, and 0/19 cases of benign pulmonary lesions. The prevalence of A. xylosoxidans in pulmonary lymphoma was not significantly higher than in benign lesions. Conclusion The present study shows that A. xylosoxidans infection may not be associated with pulmonary B-cell lymphoma in a Japanese case series. Large-scale international studies are needed to clarify the role of A. xylosoxidans in pulmonary lymphoma.

Indexed as

Achromobacter denitrificansAdultAgedBase SequenceEuropeFemaleGeographyGram-Negative Bacterial InfectionsHumansJapanLymphoma, Large B-Cell, DiffuseMaleMiddle AgedPrevalenceSequence Analysis, DNAachromobacter xylosoxidansgeographical variabilitylunglymphoma

Identifiers

PMID29151525
PMCPMC5891515
OpenAlexW2768805074

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.